Text Size
370 studies found for:    PAH

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Recruiting Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension
Interventions: Drug: Nitric Oxide;   Other: Placebo
2 Recruiting Training With Whole Body Vibration Device in Patients With PAH
Condition: Pulmonary Artery Hypertension
Intervention: Device: Exercise Group Galileo PAH
3 Recruiting Obstructive Sleep Apnea in Pulmonary Arterial Hypertension (OSA in PAH)
Conditions: Pulmonary Arterial Hypertension;   Obstructive Sleep Apnea
Intervention:
4 Recruiting Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Condition: Pulmonary Arterial Hypertension
Intervention:
5 Active, not recruiting Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
Conditions: Thalassemia Major;   Thalassemia Intermedia;   Pulmonary Arterial Hypertension
Intervention: Other: Physician standard-of-care according to ESC/ERS Guidelines
6 Active, not recruiting An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
7 Recruiting SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
8 Completed Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
Condition: Pulmonary Arterial Hypertension
Intervention:
9 Recruiting FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Placebo;   Drug: FK506 level < 2 ng/ml;   Drug: FK506 level 2-3 ng/ml;   Drug: FK506 level 3-5 ng/ml
10 Recruiting Auto-immunity and Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   HIV Infection;   Congenital Heart Defect;   Systemic Sclerosis;   Connective Tissue Disease
Interventions: Procedure: skin biopsy;   Other: Blood Sample
11 Active, not recruiting Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
12 Recruiting Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: inhaled prostacyclin;   Drug: prostacyclin;   Drug: subcutaneous and intravenous prostacyclin;   Drug: oral ERA;   Drug: oral PDE5 inhibitors
13 Completed Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Sildenafil;   Drug: Sugar Pill
14 Completed Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
15 Completed Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Other: Blood draw
16 Not yet recruiting AC-055-401 Extension, Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
17 Not yet recruiting Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Carbon Monoxide
18 Completed
Has Results 		Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sitaxentan sodium
19 Recruiting Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
20 Recruiting Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab;   Other: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years